Immediate Impact
1 from Science/Nature 58 standout
Citing Papers
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer
2024 Standout
Works of Paul Clement being referenced
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
2019
Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Paul Clement | 241 | 42 | 20 | 96 | 60 | 24 | 421 | |
| Miranda J. Rogers | 62 | 50 | 82 | 149 | 32 | 36 | 499 | |
| Michael A. Garcia | 59 | 113 | 17 | 126 | 14 | 39 | 417 | |
| Lars Daniel Berthold | 47 | 68 | 4 | 49 | 38 | 27 | 407 | |
| Waldemar Uhl | 161 | 88 | 37 | 105 | 14 | 26 | 429 | |
| Nigel Rozario | 55 | 39 | 7 | 61 | 23 | 38 | 491 | |
| John B. Selby | 52 | 60 | 13 | 77 | 58 | 26 | 510 | |
| J. Jamart | 59 | 32 | 2 | 117 | 30 | 21 | 465 | |
| Giovanna Magni | 67 | 40 | 94 | 182 | 6 | 28 | 502 | |
| Megan Fiasconaro | 153 | 34 | 39 | 106 | 5 | 38 | 473 | |
| Muhammed Bora Demirçelik | 217 | 66 | 11 | 41 | 8 | 20 | 479 |
All Works
Login with ORCID to disown or claim papers
Loading papers...